D'Agostino R B, Kannel W B, Stepanians M N, D'Agostino L C
Boston University Mathematics Department, Massachusetts 02215.
Am J Cardiol. 1993 Jan 1;71(1):82-7. doi: 10.1016/0002-9149(93)90715-o.
A previously published study reported on an open-label, multicenter study of the efficacy and tolerability of lovastatin in the management of nonfamilial primary hypercholesterolemia. In the present report the results from the 213 hypercholesterolemic patients with systemic hypertension are presented. At baseline mean +/- SD of total serum cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein (HDL) cholesterol, and the ratio of total serum cholesterol to HDL cholesterol were 268 +/- 24, 189 +/- 22 and 43 +/- 10 mg/dl and 6.6 +/- 1.6, respectively. Of the 213 hypertensive patients only 24 were not receiving antihypertensive or related cardiac medication. Baseline mean systolic and diastolic blood pressures were 140 +/- 20 and 84 +/- 9 mm Hg, respectively. Within 1 month of lovastatin therapy the observed significant reductions in total serum cholesterol, low-density lipoprotein cholesterol and the ratio of total to HDL cholesterol were 19, 27 and 24%, respectively. HDL cholesterol was increased by 6%. Diastolic blood pressure did not change significantly during this 1-month period. The 1-month lipid results were maintained over the full 6 months of the study. The dosage of lovastatin was 20 mg/day for the first month of therapy and could subsequently be adjusted to response, up to a maximum of 80 mg/day. Again, without changes in diastolic blood pressure, lovastatin was generally effective in improving the serum lipids of hypercholesterolemic hypertensive patients regardless of the type of antihypertensive medications received (including diuretics and beta blockers). Lovastatin was generally well tolerated.
一项先前发表的研究报告了一项关于洛伐他汀治疗非家族性原发性高胆固醇血症的疗效和耐受性的开放标签、多中心研究。在本报告中，呈现了213例患有系统性高血压的高胆固醇血症患者的研究结果。基线时，总血清胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白（HDL）胆固醇的均值±标准差以及总血清胆固醇与HDL胆固醇的比值分别为268±24、189±22和43±10mg/dl以及6.6±1.6。在这213例高血压患者中，只有24例未接受抗高血压或相关心脏药物治疗。基线时平均收缩压和舒张压分别为140±20和84±9mmHg。在洛伐他汀治疗的1个月内，观察到总血清胆固醇、低密度脂蛋白胆固醇以及总胆固醇与HDL胆固醇的比值分别显著降低了19%、27%和24%。HDL胆固醇增加了6%。在这1个月期间，舒张压没有显著变化。1个月的血脂结果在整个6个月的研究中得以维持。治疗的第一个月洛伐他汀的剂量为20mg/天，随后可根据反应进行调整，最大剂量为80mg/天。同样，在舒张压无变化的情况下，无论接受何种抗高血压药物（包括利尿剂和β受体阻滞剂），洛伐他汀通常都能有效改善高胆固醇血症高血压患者的血脂。洛伐他汀总体耐受性良好。
